Last updated: February 11, 2026
Clinical Trials, Market Analysis, and Projection for Propulsid (Cisapride)
What is the current status of clinical trials for Propulsid?
Propulsid (cisapride) was once marketed as a prokinetic agent for gastrointestinal motility disorders. Its marketing was discontinued in many markets due to safety concerns related to cardiac arrhythmias. Historically, clinical trials focus on evaluating efficacy and safety in specific populations, including those with gastroparesis and other motility disorders.
Recent clinical trial activities are limited. The last known significant trials, conducted by Johnson & Johnson in the late 1990s and early 2000s, aimed to evaluate its use in pediatric populations. Subsequent regulatory actions led to withdrawal from the market in 2000 in the U.S. and several other countries.
Currently, no active Phase III trials are registered or ongoing globally. Small-scale or investigator-initiated studies may exist, but these are not publicly registered or funded by major pharmaceutical companies. The clinical trial landscape indicates that Propulsid's development and testing have halted due to safety concerns and market withdrawal.
What are the legal and regulatory statuses of Propulsid?
-
United States: Market withdrawal in 2000 following FDA warnings on cardiac risks.
-
European Union: Similar withdrawal; the drug is no longer authorized.
-
Other regions: Limited or no regulatory approval; some jurisdictions restrict imports or possession.
-
Legal liabilities: Ongoing litigation connected to adverse effects, influencing companies' willingness to reintroduce or develop Propulsid.
Despite its halted market presence, patent rights related to cisapride have expired, and no active patent protections are likely to hinder repurposing efforts.
Market analysis for Propulsid
Despite its market withdrawal, the potential for reintroduction hinges on the development of safer analogs or reformulations.
-
Market Size (Pre-2000): The global market for gastrointestinal prokinetics was valued at approximately USD 0.5–1 billion, with Propulsid accounting for up to 20% of prescriptions at peak usage.
-
Current Market Opportunity: Minimal for cisapride due to safety issues. However, other drugs targeted at gastroparesis, such as metoclopramide and erythromycin, remain in use, indicating ongoing market demand.
-
Competing Drugs: Dopamine antagonists, newer prokinetics (e.g., prucalopride), and emerging therapies like gastric electrical stimulation. The market favors agents with improved safety profiles.
-
Regulatory hurdles: Reintroduction would require extensive safety data to mitigate known risks; high development and approval costs are barriers.
-
Potential for Repurposing: Modifications to cisapride's core structure or formulation could reduce cardiac risks, opening renewed market prospects.
Market projection and future outlook
-
No current commercial activity: Under the current regulatory climate, Propulsid remains inactive and unlikely to re-enter the market without significant reformulation.
-
Reformulation prospects: Pharmaceutical R&D focused on cardiac safety has increased interest in developing safer analogs. If a reformulated, safer version of cisapride emerges, potential market size could reach USD 200–500 million within 5 years, assuming successful regulatory approval and market adoption.
-
R&D investment: No significant R&D initiatives are publicly announced. Smaller biotech firms or academia may explore structural modifications to restore safety.
-
Regulatory pathway: Likely to require full safety and efficacy data, including large-scale phase III trials, at an estimated cost of USD 100–200 million.
-
Market risk: High, due to safety concerns and competition from other prokinetics with better safety profiles. Also, the shifting landscape toward non-pharmacological interventions poses additional hurdles.
Key challenges and considerations
- Safety profile: Cardiac arrhythmias associated with cisapride remain a substantial barrier.
- Patent landscape: Patent protections have expired, reducing exclusivity benefits.
- Regulatory approval: Reintroduction demands rigorous testing and approval from agencies like the FDA.
- Competition: Other drugs with similar indications have gained market share with improved safety.
- Innovation: Success depends on chemical modifications and clinical validation of safety.
Key Takeaways
- Propulsid is effectively withdrawn from the market; no active clinical development exists.
- Potential for reintegration exists if safer formulations are developed, but substantial R&D and regulatory hurdles remain.
- The market is moving toward newer, safer therapies for gastrointestinal motility disorders, limiting Propulsid's future prospects.
- The primary pathway for future market entry involves reformulation or repurposing with improved safety profiles.
FAQs
-
Why was Propulsid withdrawn from markets?
Due to safety concerns, particularly cardiac arrhythmias linked to its use.
-
Are there ongoing clinical trials for Propulsid?
No major regulatory-approved trials are active; research is limited to small or investigator-led studies.
-
Can Propulsid be repurposed?
Potentially, through reformulations designed to mitigate cardiac risks. However, this requires significant R&D investment.
-
What is the outlook for developing new drugs based on cisapride?
The outlook depends on chemical modifications to improve safety and successful regulatory approval; currently, no active programs are public.
-
What are alternative treatments for gastroparesis?
Metoclopramide, erythromycin, gastric electrical stimulation, and emerging therapies like serotonergic agonists.
References
- FDA Drug Safety Communication, 2000.
- European Medicines Agency, 2001.
- Market research reports on gastrointestinal therapeutics, 2020.
- ClinicalTrials.gov database.
- Patent database searches on cisapride and analogs.
